SK280304B6 - Liečivo na kardiálnu, ako i vaskulárnu hypertrofiu - Google Patents

Liečivo na kardiálnu, ako i vaskulárnu hypertrofiu Download PDF

Info

Publication number: SK280304B6
Authority: SK; Slovakia
Prior art keywords: methyl; butyl; chloro; biphenyl; imidazole
Prior art date: 1990-11-17

Application number

SK3471-91A

Other languages

English (en)

Slovak (sk)

Inventor

Holger Heitsch

Rainer Henning

Wolfgang Linz

Bernward Sch�Lkens

Hansj�Rg Urbach

Original Assignee

Hoechst Aktiengesellschaft

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-11-17

Filing date

1991-11-15

Publication date

1999-11-08

1991-11-15 Application filed by Hoechst Aktiengesellschaft filed Critical Hoechst Aktiengesellschaft

1999-11-08 Publication of SK280304B6 publication Critical patent/SK280304B6/sk

Links

230000000747 cardiac effect Effects 0.000 title claims abstract description 12
206010020718 hyperplasia Diseases 0.000 title claims abstract description 12
206010072810 Vascular wall hypertrophy Diseases 0.000 title claims abstract description 11
239000003814 drug Substances 0.000 title claims abstract description 6
150000003839 salts Chemical class 0.000 claims abstract description 10
PSIFNNKUMBGKDQ-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 PSIFNNKUMBGKDQ-UHFFFAOYSA-N 0.000 claims abstract description 7
KYPAHCVBAFBKAC-UHFFFAOYSA-N 2-butyl-3-[[4-(2-carboxyphenyl)phenyl]methyl]-5-chloroimidazole-4-carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 KYPAHCVBAFBKAC-UHFFFAOYSA-N 0.000 claims abstract description 4
UUPNFNCKGJOLQE-UHFFFAOYSA-N 2-[4-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]phenyl]benzoic acid Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C(O)=O)C=C1 UUPNFNCKGJOLQE-UHFFFAOYSA-N 0.000 claims abstract description 3
ZEUXAIYYDDCIRX-UHFFFAOYSA-N losartan carboxylic acid Chemical compound CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 ZEUXAIYYDDCIRX-UHFFFAOYSA-N 0.000 claims abstract 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 14
208000006029 Cardiomegaly Diseases 0.000 claims description 12
206010007572 Cardiac hypertrophy Diseases 0.000 claims description 11
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 11
-1 2 '- (1H-tetrazol-5-yl) biphenyl-4-yl Chemical group 0.000 claims description 8
159000000000 sodium salts Chemical class 0.000 claims description 5
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
102000008873 Angiotensin II receptor Human genes 0.000 claims description 2
108050000824 Angiotensin II receptor Proteins 0.000 claims description 2
JQZXGLUODAIBPF-UHFFFAOYSA-N 5-[[2-butyl-4-chloro-5-(hydroxymethyl)imidazol-1-yl]methyl]-2-phenylbenzoic acid Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC(C=C1C(O)=O)=CC=C1C1=CC=CC=C1 JQZXGLUODAIBPF-UHFFFAOYSA-N 0.000 claims 1
150000001875 compounds Chemical class 0.000 abstract description 10
238000002360 preparation method Methods 0.000 abstract description 4
239000000243 solution Substances 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000008187 granular material Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
239000000203 mixture Substances 0.000 description 4
239000002904 solvent Substances 0.000 description 4
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
239000002775 capsule Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
210000004165 myocardium Anatomy 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000008215 water for injection Substances 0.000 description 3
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
FDKIDFYIEWFERB-UHFFFAOYSA-N [2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol;potassium Chemical compound [K].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2NN=NN=2)C=C1 FDKIDFYIEWFERB-UHFFFAOYSA-N 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000001476 alcoholic effect Effects 0.000 description 2
239000002333 angiotensin II receptor antagonist Substances 0.000 description 2
210000000702 aorta abdominal Anatomy 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000008298 dragée Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
239000007903 gelatin capsule Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940102223 injectable solution Drugs 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
238000000034 method Methods 0.000 description 2
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
230000003449 preventive effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
FFVIMPKAFMFYRW-UHFFFAOYSA-N 2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid;[2-butyl-5-chloro-3-[[4-[2-(2h-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1.CCCCC1=NC(Cl)=C(C(O)=O)N1CC1=CC=C(C=2C(=CC=CC=2)C2=NNN=N2)C=C1 FFVIMPKAFMFYRW-UHFFFAOYSA-N 0.000 description 1
HLAYLOOJBAJIRU-UHFFFAOYSA-N 5-biphenyl-2-yl-1H-tetrazole Chemical group C1=CC=CC=C1C1=CC=CC=C1C1=NN=NN1 HLAYLOOJBAJIRU-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
235000019486 Sunflower oil Nutrition 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 description 1
239000010775 animal oil Substances 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
229940030600 antihypertensive agent Drugs 0.000 description 1
206010002906 aortic stenosis Diseases 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
229940045200 cardioprotective agent Drugs 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003651 drinking water Substances 0.000 description 1
235000020188 drinking water Nutrition 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
235000021323 fish oil Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
244000144993 groups of animals Species 0.000 description 1
150000002460 imidazoles Chemical class 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000005240 left ventricle Anatomy 0.000 description 1
ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
239000001095 magnesium carbonate Substances 0.000 description 1
229910000021 magnesium carbonate Inorganic materials 0.000 description 1
235000014380 magnesium carbonate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
229960002216 methylparaben Drugs 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
235000013336 milk Nutrition 0.000 description 1
239000008267 milk Substances 0.000 description 1
210000004080 milk Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
210000002464 muscle smooth vascular Anatomy 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
229940114930 potassium stearate Drugs 0.000 description 1
ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical compound CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
150000003233 pyrroles Chemical class 0.000 description 1
230000001373 regressive effect Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000002600 sunflower oil Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
150000003852 triazoles Chemical class 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Recrystallisation Techniques (AREA)
Compounds Of Unknown Constitution (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SK3471-91A 1990-11-17 1991-11-15 Liečivo na kardiálnu, ako i vaskulárnu hypertrofiu SK280304B6 (sk)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE4036706A DE4036706A1 (de)	1990-11-17	1990-11-17	Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie

Publications (1)

Publication Number	Publication Date
SK280304B6 true SK280304B6 (sk)	1999-11-08

Family

ID=6418475

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK3471-91A SK280304B6 (sk)	1990-11-17	1991-11-15	Liečivo na kardiálnu, ako i vaskulárnu hypertrofiu

Country Status (20)

Country	Link
US (1)	US5236943A (fr)
EP (1)	EP0492105B1 (fr)
JP (1)	JP3370347B2 (fr)
KR (1)	KR100221686B1 (fr)
CN (1)	CN1049116C (fr)
AT (1)	ATE108656T1 (fr)
AU (1)	AU652590B2 (fr)
BR (1)	BR9104918A (fr)
CA (1)	CA2055637C (fr)
CZ (1)	CZ283236B6 (fr)
DE (2)	DE4036706A1 (fr)
DK (1)	DK0492105T3 (fr)
ES (1)	ES2060274T3 (fr)
HR (1)	HRP940765B1 (fr)
HU (1)	HU219404B (fr)
IE (1)	IE66461B1 (fr)
MX (1)	MX9102100A (fr)
NO (1)	NO914482L (fr)
SK (1)	SK280304B6 (fr)
ZA (1)	ZA919056B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6034114A (en) *	1990-12-14	2000-03-07	Smithkline Beecham Plc	Medicament
US5616599A (en) *	1991-02-21	1997-04-01	Sankyo Company, Limited	Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
US5266583A (en) *	1992-09-01	1993-11-30	Merck & Co., Inc.	Angitotensin II antagonist
US5264447A (en) *	1992-09-01	1993-11-23	Merck & Co., Inc.	Angiotensin II antagonist
JP3501484B2 (ja) *	1992-12-17	2004-03-02	三共株式会社	ビフェニル誘導体
US5908858A (en)	1996-04-05	1999-06-01	Sankyo Company, Limited	1,2-diphenylpyrrole derivatives, their preparation and their therapeutic uses
WO1998025896A1 (fr) *	1996-12-10	1998-06-18	G.D. Searle & Co.	Composes de pyrrolyle substitues destines au traitement de l'inflammation
WO1998037068A1 (fr)	1997-02-21	1998-08-27	Bristol-Myers Squibb Company	Derives d'acide benzoïque et composes apparentes utilises comme agents antiarythmiques
ES2154191B1 (es) *	1998-11-24	2001-10-16	Ferrer Int	Nuevos acetales derivados de los 2-alquil-5-halo-3-(2'-(tetrazol-5-il)-bifenil-4-ilmetil)-3h-imidazol-4-carbaldehidos.
SE9903028D0 (sv)	1999-08-27	1999-08-27	Astra Ab	New use
EP1427408A4 (fr) *	2001-09-17	2005-10-26	Bristol Myers Squibb Co	Acides hydroxamiques cycliques utilises comme inhibiteurs de metalloproteinases matricielles et/ou d'enzyme de conversion du tnf-$g(a) (tace)
ITTO20040264A1 (it) *	2004-04-28	2004-07-28	Rotta Res Lab Spa	Nuovi derivati pirrolici ad attivita' angiotensina-ii antagonista
WO2006029057A1 (fr) *	2004-09-02	2006-03-16	Teva Pharmaceutical Industries, Ltd.	Epuration d'olmesartan medoxomil
CN1993355A (zh) *	2004-09-02	2007-07-04	特瓦制药工业有限公司	奥美沙坦酯的纯化方法
US20070054948A1 (en) *	2004-09-02	2007-03-08	Lilach Hedvati	Purification of olmesartan medoxomil
US20060258727A1 (en) *	2005-01-03	2006-11-16	Lilach Hedvati	Olmesartan medoxomil with reduced levels of impurities
MX2010000465A (es)	2007-07-12	2010-08-30	Tragara Pharmaceuticals Inc	Metodos y composiciones para el tratamiento de cancer, tumores y alteraciones relacionadas con tumores.
DK2318007T3 (da)	2008-08-15	2013-03-25	N30 Pharmaceuticals Inc	Nye pyrrol-inhibitorer af s-nitrosoglutathion-reduktase som terapeutiske midler
EP2315590B1 (fr)	2008-08-15	2012-09-26	N30 Pharmaceuticals, LLC	Inhibiteurs pyrroliques de la s nitrosoglutathion réductase
HUE031580T2 (en)	2008-08-15	2017-07-28	Nivalis Therapeutics Inc	Novel pyrrole inhibitors of s-nitrosoglutathione reductase as therapeutic agents
CN102816126A (zh) *	2011-06-07	2012-12-12	中国药科大学	具有心血管活性的胺磺酰芳基取代的三氮唑类衍生物、其制备方法及用途
EP3886854A4 (fr)	2018-11-30	2022-07-06	Nuvation Bio Inc.	Composés pyrrole et pyrazole et leurs procédés d'utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US488084A (en) *		1892-12-13		Blank-feeding device
JPS5671074A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	1,2-disubstituted-4-halogenoimidazole-5-acetic acid derivative
JPS5671073A (en) *	1979-11-12	1981-06-13	Takeda Chem Ind Ltd	Imidazole derivative
US4820843A (en) *	1987-05-22	1989-04-11	E. I. Du Pont De Nemours And Company	Tetrazole intermediates to antihypertensive compounds
US5015651A (en) *	1988-01-07	1991-05-14	E. I. Du Pont De Nemours And Company	Treatment of hypertension with 1,2,4-angiotensin II antagonists
US4880804A (en) *	1988-01-07	1989-11-14	E. I. Du Pont De Nemours And Company	Angiotensin II receptor blocking benzimidazoles
CA1338238C (fr) *	1988-01-07	1996-04-09	David John Carini	Imidazoles bloquant les recepteurs de l'angiotensine ii et combinaisons de ces imidazoles avec des diuretiques et des anti-inflammatoires non steroidiens
GB8820844D0 (en) *	1988-09-05	1988-10-05	Pfizer Ltd	Therapeutic agents
US4916129A (en) *	1989-01-19	1990-04-10	E. I. Du Pont De Nemours And Company	Combination β-blocking/angiotensin II blocking antihypertensives
IL95975A (en) *	1989-10-24	1997-06-10	Takeda Chemical Industries Ltd	N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
DE4010797A1 (de) *	1990-04-04	1991-10-10	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
US5196444A (en) *	1990-04-27	1993-03-23	Takeda Chemical Industries, Ltd.	1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
DE4023215A1 (de) *	1990-07-21	1992-01-23	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, sie enthaltende mittel und deren verwendung
DE4036645A1 (de) *	1990-11-16	1992-05-21	Hoechst Ag	Substituierte azole, verfahren zu deren herstellung, deren enthaltende mittel und deren verwendung

1990
- 1990-11-17 DE DE4036706A patent/DE4036706A1/de not_active Withdrawn
1991
- 1991-11-11 AT AT91119183T patent/ATE108656T1/de not_active IP Right Cessation
- 1991-11-11 EP EP91119183A patent/EP0492105B1/fr not_active Expired - Lifetime
- 1991-11-11 ES ES91119183T patent/ES2060274T3/es not_active Expired - Lifetime
- 1991-11-11 DK DK91119183.1T patent/DK0492105T3/da active
- 1991-11-11 DE DE59102259T patent/DE59102259D1/de not_active Expired - Lifetime
- 1991-11-13 BR BR919104918A patent/BR9104918A/pt unknown
- 1991-11-14 US US07/791,501 patent/US5236943A/en not_active Expired - Lifetime
- 1991-11-15 ZA ZA919056A patent/ZA919056B/xx unknown
- 1991-11-15 CA CA002055637A patent/CA2055637C/fr not_active Expired - Lifetime
- 1991-11-15 AU AU87858/91A patent/AU652590B2/en not_active Expired
- 1991-11-15 JP JP32666391A patent/JP3370347B2/ja not_active Expired - Lifetime
- 1991-11-15 CZ CS913471A patent/CZ283236B6/cs not_active IP Right Cessation
- 1991-11-15 HU HU581/91A patent/HU219404B/hu unknown
- 1991-11-15 NO NO91914482A patent/NO914482L/no unknown
- 1991-11-15 IE IE399291A patent/IE66461B1/en not_active IP Right Cessation
- 1991-11-15 SK SK3471-91A patent/SK280304B6/sk not_active IP Right Cessation
- 1991-11-15 KR KR1019910020342A patent/KR100221686B1/ko not_active Expired - Lifetime
- 1991-11-15 MX MX9102100A patent/MX9102100A/es unknown
- 1991-11-16 CN CN91110817A patent/CN1049116C/zh not_active Expired - Lifetime
1994
- 1994-10-25 HR HR940765A patent/HRP940765B1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
CA2055637A1 (fr)	1992-05-18
BR9104918A (pt)	1992-06-23
AU652590B2 (en)	1994-09-01
HRP940765A2 (en)	1997-08-31
JPH04290823A (ja)	1992-10-15
HRP940765B1 (en)	2000-08-31
CN1062289A (zh)	1992-07-01
AU8785891A (en)	1992-05-21
KR100221686B1 (ko)	1999-09-15
ES2060274T3 (es)	1994-11-16
JP3370347B2 (ja)	2003-01-27
IE66461B1 (en)	1995-12-27
ATE108656T1 (de)	1994-08-15
NO914482L (no)	1992-05-18
KR920009393A (ko)	1992-06-25
EP0492105A3 (en)	1992-07-29
CA2055637C (fr)	2003-11-11
EP0492105B1 (fr)	1994-07-20
US5236943A (en)	1993-08-17
CS347191A3 (en)	1992-06-17
NO914482D0 (no)	1991-11-15
HUT59599A (en)	1992-06-29
DE4036706A1 (de)	1992-05-21
IE913992A1 (en)	1992-05-20
HU219404B (hu)	2001-04-28
CN1049116C (zh)	2000-02-09
MX9102100A (es)	1992-07-08
HU913581D0 (en)	1992-01-28
ZA919056B (en)	1992-07-29
DE59102259D1 (de)	1994-08-25
DK0492105T3 (da)	1994-11-07
EP0492105A2 (fr)	1992-07-01
CZ283236B6 (cs)	1998-02-18

Legal Events

Date	Code	Title	Description
2012-01-04	MK4A	Patent expired	Expiry date: 20111115

Publication	Publication Date	Title
CZ283236B6 (cs)	1998-02-18	Blokátory angiotensin-II-receptoru a jejich použití
US3980791A (en)	1976-09-14	Tetramisole and levamisole pour-on anthelmintic compositions and methods of use
EP0628313B1 (fr)	2005-11-30	Combinaison d'un benzimidazole ayant une activité antagoniste de l'angiotensine-II avec manidipine pour le traitement de la hypertension arterielle
JP2930252B2 (ja)	1999-08-03	アンジオテンシン−▲ｉｉ▼受容体拮抗剤およびカルシウムチャンネルブロッカーの新規組成物
JP2008019273A (ja)	2008-01-31	虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
EP1870098A2 (fr)	2007-12-26	Utilisation combinée de valsaratan et bloqueurs du canal de calcium à buts thérapeutiques
JP2002537258A (ja)	2002-11-05	高血圧の治療のための医薬
RU2367442C2 (ru)	2009-09-20	Способ нормализации мочеиспускания при нарушении функции почек
EP0426066A2 (fr)	1991-05-08	Inhibiteurs de l'ACE pour prévenir le déclenchement du diabète du type II
SK74995A3 (en)	1996-05-08	Antihyperglicemicly efficient pharmaceutical agents
CZ301913B6 (cs)	2010-07-28	Farmaceutický prípravek pro predcházení, lécení nebo inhibování vývoje jednoduché retinopatie nebo predproliferacní retinopatie
US8455526B2 (en)	2013-06-04	Therapeutic use of imidazole-5-carboxylic acid derivatives
CZ290155B6 (cs)	2002-06-12	Léčivo pro léčení několikanásobné poruchy systémových orgánů
EP0660713B1 (fr)	2001-10-24	Utilisation d'agents antagonistes de l'angiotensine ii dans le traitement de l'hypertrophie ventriculaire gauche
US5466713A (en)	1995-11-14	Iloprost with action against cerebral malaria
EA007952B1 (ru)	2007-02-27	Применение ирбесартана для изготовления лекарств, которые пригодны для предупреждения или лечения лёгочной артериальной гипертензии
SK78994A3 (en)	1995-07-11	Optic hypotensive agent and method of its preparation
DE69430766T2 (de)	2003-02-06	Vasculäre Hypertrophicsuppressor
DK166755B1 (da)	1993-07-12	Farmaceutisk praeparat indeholdende en angiotensin-omdannende enzym-inhibitor og et sloejfediuretikum og fremgamgsmaade til fremstilling af praeparatet
EP0439320A1 (fr)	1991-07-31	Traitement des dysfonctionnements érectiles
AU774855B2 (en)	2004-07-08	Use of moxonidine for postmyocardial infarction treatment
KR930004647B1 (ko)	1993-06-02	신장 질환 치료제
KR100222627B1 (ko)	1999-10-01	앙기오텐신-ii 수용체 길항제 및 칼슘 채널 차단제의 신규한 조성물
JP2949366B2 (ja)	1999-09-13	心臓疾患の予防または治療剤
JPH0873352A (ja)	1996-03-19	高血圧治療剤